Zentalis Pharmaceuticals (ZNTL) Asset Writedowns and Impairment (2021 - 2025)

Zentalis Pharmaceuticals' Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at $3.0 million for Q4 2025.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $3.0 million in Q4 2025; TTM through Mar 2026 was $3.0 million, a 159.03% increase from a year earlier, with the FY2025 full-year figure at $4.1 million, changed N/A from the prior year.
• Asset Writedowns and Impairment grew to $3.0 million in Q4 2025 per ZNTL's latest filing, from $1.2 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $5.0 million in Q1 2023 and bottomed at -$8.8 million in Q4 2021.
• The 3-year median for Asset Writedowns and Impairment is $2.1 million (2025), against an average of $72250.0.